Tcl1 peptides for immunotherapy
AssigneeBoard of Regents, The University of Texas System
InventorsSattva S. Neelapu, Jinsheng Weng
Life of this patent
Estimating the term…
Abstract
Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided.
Claims56
An isolated peptide 45 amino acids in length or less and comprising the sequence of TCL165-78 (SEQ ID NO:2) or TCL171-78 (SEQ ID NO:11) or a sequence having at least 90% identity to TCL165-78 (SEQ ID NO:2) or TCL171-78 (SEQ ID NO:11), wherein the peptide selectively binds HLA-A2 or HLA-A*0201.
Dependencies are inferred from the claim text.